Preclinical Proof-of-Concept: A Novel Hybrid Gene Therapy Approach to Treat Severe Early-Onset Ornithine Transcarbamylase Deficiency

被引：0

作者：

Kok, Bernard ^{[1
]}

Ebeid, David ^{[2
]}

Mishgin, Nairika ^{[2
]}

Loveless, Ryan ^{[2
]}

Hajj, Khal ^{[2
]}

Nguyen, Tuyen ^{[2
]}

Deng, Christopher ^{[2
]}

Griffin, Peter ^{[2
]}

Li, Mu ^{[2
]}

Bennett, Michael ^{[2
]}

Battiprolu, Pavan ^{[2
]}

Warner, Brent ^{[2
]}

Madison, Blair ^{[2
]}

Rychak, Joshua ^{[2
]}

机构：

[1] Poseida Therapeut, In Vivo Gene Therapy, San Diego, CA USA

[2] Poseida Therapeut, San Diego, CA USA

来源：

MOLECULAR THERAPY | 2023年 / 31卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

127

引用

页码：68 / 69

页数：2

共 47 条

[1] Establishing Preclinical Proof-of-Concept of Gene Therapy for Huntington Disease
Evers, Melvin
NEUROLOGY, 2018, 90
[2] Interdisciplinary treatment of early-onset ornithine transcarbamylase (OTC) deficiency.: Two case reports and a review
Hübler, A
Seidel, J
Patzer, L
Bellstedt, K
Schramm, D
ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2001, 205 (06): : 236 - 241
[3] Preclinical proof-of-concept for hematopoietic stem cell based gene therapy for aids.
Plavec, I
Bonyhadi, M
Veres, G
Junker, U
Kaneshima, H
Bohnlein, E
BLOOD, 1996, 88 (10) : 1072 - 1072
[4] Proof-of-concept for a gene replacement approach to CDKL5 deficiency disorder
Benke, Tim A.
Kind, Peter C.
BRAIN, 2020, 143 : 716 - 718
[5] Gene therapy targeting INa to treat life-threatening arrhythmias: beyond proof-of-concept?
Lugenbiel, Patrick
EUROPEAN HEART JOURNAL, 2025,
[6] A Novel Approach to Treat Stuttering: Preclinical Gene Therapy in Animal Studies
Bragg, Camryn
Zhang, Ruli
SheikhBahaei, Shahriar
MOLECULAR THERAPY, 2024, 32 (04) : 484 - 484
[7] A NOVEL POINT MUTATION AT CODON-269 OF THE ORNITHINE TRANSCARBAMYLASE (OTC) GENE CAUSING NEONATAL ONSET OF OTC DEFICIENCY
ZIMMER, KP
MATSUURA, T
COLOMBO, JP
KOCH, HG
ULLRICH, K
DEUFEL, T
HARMS, E
MATSUDA, I
JOURNAL OF INHERITED METABOLIC DISEASE, 1995, 18 (03) : 356 - 357
[8] A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency
Wang, Lili
Yang, Yang
Breton, Camilo
Bell, Peter
Li, Mingyao
Zhang, Jia
Che, Yan
Saveliev, Alexei
He, Zhenning
White, John
Latshaw, Caitlin
Xu, Chenyu
McMenamin, Deirdre
Yu, Hongwei
Morizono, Hiroki
Batshaw, Mark L.
Wilson, James M.
SCIENCE ADVANCES, 2020, 6 (07)
[9] Development of a novel AAV-based gene therapy in combination with tolerogenic nanoparticles for sustained treatment of ornithine transcarbamylase deficiency
De Sabbata, G.
Boisgerault, F.
Guarnaccia, C.
Bortolussi, G.
Collaud, F.
Iaconcig, A.
Sola, M. L. S.
Charles, S.
Leborgne, C.
Nicastro, E.
Ilyinskii, P.
Kishimoto, T. K.
D'Antiga, L.
Mingozzi, F.
Muro, A. F.
HUMAN GENE THERAPY, 2018, 29 (12) : A128 - A128
[10] Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction
Sheppard, M.
Spencer, R. N.
Ashcroft, R.
David, A. L.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2016, 47 (04) : 484 - 491

← 1 2 3 4 5 →